Supplementary Table 4. Association between serum IGF-1 level and 3-month functional outcome

Serum IGF-1	OR [95% CI]	p
Model 1		0.191
Q1	Reference	
Q2	1.31 [0.73–2.35]	0.371
Q3	1.31 [0.73–2.38]	0.368
Q4	1.97 [1.07–3.64]	0.030
Model 2		0.584
Q1	Reference	
Q2	0.95 [0.51–1.78]	0.875
Q3	0.65 [0.33–1.27]	0.206
Q4	0.86 [0.42–1.74]	0.673
Model 3		0.172
Q1	Reference	
Q2	0.74 [0.34–1.64]	0.460
Q3	0.36 [0.15–0.84]	0.019
Q4	0.60 [0.24–1.49]	0.269

Model 1: crude OR; model 2: model 1 adjusted for age and sex; model 3: model 2 adjusted for body mass index, Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, diabetes mellitus, previous stroke, smoking, initial National Institutes of Health Stroke Scale score, white blood cell count, initial glucose level, and high-sensitivity C-reactive protein.
CI: confidence interval, IGF-1: insulin-like growth factor-1, OR: odds ratio.